KPV — Wolverine Health

How it works

The three C-terminal amino acids of alpha-MSH — responsible for most of its anti-inflammatory activity in cell studies. It blocks NF-κB signalling and reduces pro-inflammatory cytokine production. In animal models of gut inflammation it reduces colitis severity. The oral route interests researchers because IBD affects the gut: if KPV survives digestion, it could hit inflamed tissue directly. That's a big if. Human trials don't exist yet.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status: Permitted in sport
Route: subcutaneous injection; oral (gastrointestinal inflammation research)

Key studies

Alpha-MSH and its C-terminal tripeptide KPV — anti-inflammatory properties — Bhardwaj et al.

KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, retains the full anti-inflammatory activity of alpha-MSH in keratinocyte models, inhibiting IL-1-stimulated cytokine production.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on KPV

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

Anti-inflammatory peptides: mechanism, evidence, and what the human data is missing

WADA

Three peptides under FDA review have animal-model anti-inflammatory evidence: KPV, BPC-157, GHK-Cu. Each engages the inflammatory cascade at a different point. None has a controlled human trial in an inflammatory indication. Here is where the three files diverge.

KPV: Anti-Inflammatory Peptide Research and the PCAC July 2026 Docket

Science-journalism overview of KPV — the alpha-MSH tripeptide fragment studied for gut inflammation and wound healing, its evidence base, and its position on the PCAC July 23–24 2026 review agenda.